Evidence map›Paper›PMID 35139400›Full record

SynthesisJournal of hepatology2022

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.

Amit G Singal, Emily Zhang, Manasa Narasimman, Nicole E Rich, Akbar K Waljee, Yujin Hoshida, Ju Dong Yang, Maria Reig, Giuseppe Cabibbo, Pierre Nahon and 2 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07764835 (Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients Using Semiannual Ultrasound LI-RADS and Alpha-Fetoprotein), which is not on this map. Cited by 247 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
247citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07764835 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients Using Semiannual Ultrasound LI-RADS and Alpha-Fetoprotein: A Multicenter Real-World Observational Study

Typeobservational_patient_registrySponsorD'Or Institute for Research and EducationRan2026 to 2029Enrolled300ConditionsHepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
3 · Its place in the literature

Who cites it

247 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Pooled it
  8. Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  9. Trial
  10. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    Trial
  11. Trial
  12. Review
  13. ALPS-HCC Score: A Dynamic Liver Stiffness Measurement-Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

187 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Amit G SingalDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States. Electronic address: amit.singal@utsouthwestern.edu.
Emily ZhangDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Manasa NarasimmanDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Nicole E RichDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Akbar K WaljeeDepartment of Internal Medicine, University of Michigan, Ann Arbor MI, United States.
Yujin HoshidaDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Ju Dong YangKarsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai, Los Angeles, CA, United States.
Maria ReigBarcelona Clinic Liver Cancer (BCLC) Group, Hospital Clinic de Barcelona, CIBEREEHD, Barcelona University, Barcelona, Spain.
Giuseppe CabibboSection of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
Pierre NahonAP-HP, Hôpital Avicenne, Liver Unit, Université Sorbonne Paris Nord, Bobigny, France; Inserm, UMR-1138 Université de Paris, Paris, France.
Neehar D ParikhDepartment of Internal Medicine, University of Michigan, Ann Arbor MI, United States.
Jorge A MarreroDepartment of Internal Medicine, University of Pennsylvania, Philadelphia PA, United States.

Funding

Training Program in Gastrointestinal EpidemiologyT32DK062708 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter D.R. Higgins, Elliot Tapper · 2003 to 2026
$3.9M
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6M
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United StatesU01CA230694 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2022
$3.5M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTIONU01CA230669 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOK, ANNA S.F., SU, GRACE L. · 2018 to 2022
$3.3M
Harms of Hepatocellular Carcinoma Screening in Patients with CirrhosisR01CA212008 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2017 to 2022
$3.2M
Precision Screening for Hepatocellular Carcinoma in Patients with CirrhosisR01CA222900 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2023
$2.4M
NCI NIH HHS R01 CA212008NCI NIH HHS R01 CA222900NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS U01 CA230669NCI NIH HHS U01 CA230694NIDDK NIH HHS T32 DK062708
6 · The paper itself

Abstract

BACKGROUND &

aimsThere is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we conducted a systematic review and meta-analysis of cohort studies evaluating the benefits and harms of HCC surveillance in patients with cirrhosis.

methodsWe performed a search of the Medline and EMBASE databases and national meeting abstracts from January 2014 through July 2020 for studies reporting early-stage HCC detection, curative treatment receipt, or overall survival, stratified by HCC surveillance status, among patients with cirrhosis. Pooled risk ratios (RRs) and hazard ratios, according to HCC surveillance status, were calculated for each outcome using the DerSimonian and Laird method for random effects models.

resultsWe identified 59 studies including 145,396 patients with HCC, which was detected by surveillance in 41,052 (28.2%) cases. HCC surveillance was associated with improved early-stage detection (RR 1.86, 95% CI 1.73-1.98; I

conclusionHCC surveillance is associated with improved early detection, curative treatment receipt, and survival in patients with cirrhosis, although there was heterogeneity in pooled estimates. Available data suggest HCC surveillance is of high value in patients with cirrhosis, although continued rigorous studies evaluating benefits and harms are still needed. LAY SUMMARY: There has been ongoing debate about the overall value of hepatocellular carcinoma (HCC) screening in patients with cirrhosis given the lack of data from randomized-controlled trials. In a systematic review of contemporary cohort studies, we found that HCC screening is associated with improved early detection, curative treatment receipt, and survival in patients with cirrhosis, although there were fewer data quantifying potential screening-related harms. Available data suggest HCC screening is of high value in patients with cirrhosis, although continued studies evaluating benefits and harms are still needed.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsEarly DiagnosisHumansLiver CirrhosisMass Screeningcirrhosisearly detectionliver cancerScreeningultrasound

Identifiers

PMID35139400
PMCPMC9232881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.